When we first invested in Implicity in 2019, the company only had one year of deployment in France. Three years later, Implicity turned into a French leader in remote monitoring of cardiac implantable electronic devices, with 60 000+ patients monitored, a 40% market share and a research partnership with the country’s Health Data Hub. It has also started its global expansion, with clients in the US, UK, Germany and Finland. Well done!
Given this impressive path, we didn’t think long before joining Implicity’s 21M€ Series A, alongside Crédit Mutuel Innovations, Bpifrance, Serena Capital, Karista and BNPP Dev. Especially since the company is still far from having revealed its full potential, as the pandemic gave a boost to telemedicine and remote assistance.
Implicity has developed the first AI-powered universal cardiac monitoring platform aggregating and processing data from cardiac implantable electronic devices and external devices (such as connected weight scales) whatever the manufacturer or device model. Having all data in one platform is extremely convenient and useful for managing patient clinical situations. Thanks to Implicity Saas platform, medical staff can cope with the data tsunami from cardiac implants and external devices, boost their productivity and increase their quality of care.
Implicity is also developing and integrating over time in its platform medical algorithms which are digital medical devices.
For example, Implicity obtained at the end of 2021 the FDA clearance for its digital medical device reducing the false positives from Implantable Loop Recorders which is the fastest growing segment among cardiac implants.
To progress toward a more predictive and data-based medicine, Implicity is also one of the very few companies allowed to work with the French Health Data Hub. Thanks to its access to the Health Data Hub, Implicity ambitions to develop a solution to predict heart failure crisis thus reducing patient hospitalization and reducing Healthcare costs
More than ever, we believe that Arnaud Rosier – the CEO and cardiologist himself – and his team are well positioned to develop the next generation cardiac remote monitoring solutions that will become new standards of care.
